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On the Trail of PrometheusThe Greek gods punished Prome-
theus for giving their fire to humans.
Each day, an eagle would tear out
his liver; every night it would grow
back again. Although bodily regen-
eration has existed in myth for mil-
lennia, only certain tissues will, in
fact, regenerate. Over the last two
decades, many companies have
tried to transform regenerative abil-
ity into reality.
The first wave of tissue-engi-
neering companies, founded in the
1990’s, were impaled on an ugly re-
ality: making a complex functional
organ was not possible with the sci-
entific knowledge at hand. ‘‘The two
big ones that went down, Advanced
Tissue Sciences and Organogene-
sis, really gave the field a wakeup
call,’’ says Dr. Stephen Badylak, di-
rector of the McGowan Institute for
Regenerative Medicine at the Uni-
versity of Pittsburgh. The first com-
panies did not have products that
could pass the FDA or show signifi-
cant advantages over existing tech-
nology and practices for their cost.
Between 2000 and 2002, the over-
all activity in the field dropped 90%,
according to a survey conducted by
Dr. Michael Lysaght, director of the
Brown University Center for Bio-
medical Engineering. Yet over the
last few years, tissue engineering,
now dubbed ‘‘regenerative medi-
cine,’’ has begun cropping up again
at investor conferences. ‘‘Almost ev-
ery university has research in this
area,’’ says Dr. Anthony Atala, direc-
tor of the Institute of Regenerative
Medicine at Wake Forest University
and founder of Tengion (http://
www.tengion.com/). In its new in-
carnation, tissue engineering covers
all aspects of the repair or replace-
ment of tissues and organs by incor-
porating the use of cells, genes, or
other biological building blocks
along with bioengineered materials
and technologies. Atala notes that
advances in stem cell research have
brought new vigor to the field.
Small companies are sprouting
up again, and giants, like Smith &
Nephew, Johnson & Johnson,Medtronic, and Genyzme, have a
variety of tissue-engineering pro-
grams. Organogenesis was revived
and is now churning out artificial
skin. But for most companies, com-
mercialization beyond the research
stage still lags. Few products are
making it to market, and they tend
to be relatively simple components:
tissues, such as artificial skin, or
matrices for seeding human cells,
such as decellularized bone and
cartilage. One promising approach
is to make hybrid devices, like
those made by Rhode Island-based
RenaMed Biologics, Inc. (http://
www.nephrostherapeutics.com/).
The company’s product being de-
veloped in collaboration with Gen-
zyme is an external device meant to
supplement dialysis for people with
acute renal failure. Patients’ blood
is filtered through a hollow fiber car-
tridgecontaining renalepithelial cells,
which perform certain metabolic
functions in lieu of a natural kidney.
‘‘Tissue engineering cov-
ers all aspects of the
repair or replacement of
tissues and organs by
incorporating the use of
cells, genes, or other bio-
logical building blocks
along with bioengineered
materials and technol-
ogies.’’
Blood Vessels on a Shoestring
Cytograft Tissue Engineering,
founded in 2000 (http://www.
cytograft.com/) in Novato, Califor-
nia, is constructing autologous
blood vessels for peripheral and
coronary bypass surgery. Last year
at the American Heart Association
conference, Cytograft presented the
first human use of a small diameter
engineered blood vessel. ‘‘The real
home run in vascular surgery ishigh-pressure arterial bypass grafts
for coronary, for lower limb bypass,
or for AV [arteriovenous—directly
connecting artery to vein] shunts,’’
says Todd McAllister, company co-
founder.
So far, the company has inserted
their engineered blood vessels in
an AV shunt application in two pa-
tients with end stage renal disease.
The company is now enrolling pa-
tients in clinical trials at three differ-
ent centers worldwide and antici-
pates submitting an Investigational
New Drug application in June.
Cytograft constructs its veins by
growing sheets of cells and rolling
them over a temporary support
mandrel. Once the roll has fused
into a uniform tissue, the tube is
lined with a second cell type to pre-
vent blood from clotting. Both cell
types are harvested from each
patient. ‘‘We can achieve requisite
mechanical strength without the in-
clusion of synthetic materials,’’
McAllister says. Building a personal-
ized blood vessel currently takes six
months, but McAllister expects to
gain efficiencies through process
optimization. The company is now
working to produce an off-the-shelf
product with a tube built from a uni-
versal donor and then lined with
autologous endothelial cells. The
ten-person company has raised
$3.5 million from NIH and $4.5 mil-
lion in private equity.
The Skin Game
The granddaddy of tissue engineer-
ing is Integra (http://www.integra-
ls.com/), a pliable artificial scaffold
developed thirty years ago in the lab-
oratory of Ioannis Yannas, professor
of polymer science and engineering
at MIT, and Dr. John F. Burke, then
director of the Burn Center at Massa-
chusetts General Hospital and
Shriners Burn Institute. Integra en-
ables badly burned patients to re-
generate the dermis layer of skin
without scarring. The dermis does
not regrow spontaneously in adults.
The process takes 18 days and re-
quires two operations. Once Integra
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must then be covered with an epi-
dermal graft. In the fresh wound,
the scaffold disrupts the scarring
process by providing binding sites
that are specific for scar-producing
cells. As the new tissue forms, the
scaffold degrades. Integra was ap-
proved by the FDA in 1996.
‘‘We can synthesize organs in
adults,’’ says Yannas. ‘‘They are not
perfect, but they are clinically use-
ful.’’ In addition to adult skin (albeit
without hair or sweat glands), Yan-
nas’ lab has grown peripheral nerves
to certain distances and conjunctiva,
the organ underneath the eyelid that
induces tearing. ‘‘We do not believe
that the best way to reach the clinic
is to try to synthesize an organ
in vitro,’’ Yannas says. ‘‘In my opin-
ion, there is no limit to how you can
grow organs in adults using scaf-
folds with very high biological activ-
ity. You do not have to add stem
cells. You do not need to add wound
growth factors. That’s because the
wound already has all these things
in it. What the wound doesn’t have
is an active scaffold because it
goes about destroying its own ma-
trix in order to form a scar.’’
Other autologous skin grafts in-
clude Epicel, developed by Drs.
Howard Green of Harvard and Eu-
gene Bell of MIT and licensed
by Genzyme Tissue Repair (http://
www.genzyme.com/), Organogen-
esis’ (http://www.organogenesis.
com/) graft Apligraf, which has living
cells in it and was approved by
the FDA for venous ulcers, and
Ortec International’s (http://www.
ortecinternational.com/) OrCel, a
collagen-based skin dressing de-
signed on similar principles as
Integra.
Grafting in the Burn Ward
Dr. David Barillo (COL USAISR-Ft.
Sam Houston) is an Army surgeon
who treats soldiers as well as civilian
burn victims at the Army Burn Cen-
ter in San Antonio, Texas.
‘‘We get a lot of business from
Iraq,’’ Barillo says. Because of im-
proved medical care and logistics,
the Army can save more soldiers,
but the ones they save are more
severely injured. ‘‘We try to get as
much of the burn off as quickly as
possible,’’ Barillo says. The faster
the burn is excised and covered,
the better. But patients with largeburns over 50% or 60% of their bod-
ies may not have skin to spare for
grafts; thus, Barillo and his fellow
surgeons use temporary dressings,
‘‘a lot of Integra,’’ as well as cadaver
skin. Barillo emphasized the need
for off-the-shelf skin that can be ap-
plied when needed, especially criti-
cal for patients who have large
burns on 80% to 90% of their bod-
ies. Saving their lives uses up all
their available skin; there is none to
spare for reconstruction.
According to Barillo, the more dif-
ficult patients are the ones who suffer
from deep injuries. The doctors can
only replace skin, not muscle. ‘‘There
is a tremendous interest: can we re-
generate muscle, can we regenerate
functional tissue, can we regenerate
nerves to hook everything up?’’ Ba-
rillo notes that the center is planning
some collaborative research with
the Wake Forest Institute of Regen-
erative Medicine on tissue engineer-
ing for reconstructive surgery.
Making It to the Transplant
Organ transplantation techniques
have improved immensely over
the past fifty years, to the extent
that the number of available organs
doesn’t meet demand. The United
Network for Organ Sharing website
lists over 91,000 people waiting for
various organs. Even when a trans-
plant is successful, patients depend
on immunosuppressant drugs that
have numerous side effects that im-
pact quality of life.
Growing organs or tissues from
a patient’s own cells could poten-
tially solve problems both of avail-
ability and compatibility. But creat-
ing a fully functional organ proves
to be an extremely difficult technical
challenge. Growing an organ in vivo
holds the promise of harnessing the
body’s healing capacity. Many re-
searchers working in the field are
taking this path by seeding matrixes
with a patient’s own cells and im-
planting them, hoping the body can
provide better growing conditions
than can be generated in a lab.
‘‘Everything South of the Kidneys’’
In his 16 years working as a urologic
surgeon, Dr. Anthony Atala has built
up a number of patents regarding
the urogenital system. At the Wake
Forest Institute ofRegenerative Med-
icine, which he has directed since
2003, Atala and other researchersgrow pancreas tissue, blood ves-
sels, livers, and heart tissue.
At Children’s Hospital in Boston,
Atala and colleagues developed au-
tologous organs such as bladders,
kidneys, and penis tissue. In 1999,
Atala’s team published results on
growing functional bladders in ani-
mals. The proof of concept was
followed by a limited human trial.
Atala’s bladder patents from his
work at Children’s changed hands a
few times and in 2003, were licensed
by Tengion. The 45-person com-
pany received approximately $39
million in venture capital funding as
well as financial inducements from
the Winston-Salem city council
and business community to locate
there. Tengion recently signed a col-
laborative ‘‘multimillion dollar and
multiyear’’ deal with Wake Forest
University, funding research there
in exchange for the right to commer-
cialize the results.
A bladder is a reservoir made of
smooth muscle and connected to
the brain and spinal cord by nerves
that sense when it is full. ‘‘It is actually
quite a complex organ,’’ Atala says.
Currently, if a bladder replacement
is needed, the solution is substituting
a piece of bowel tissue. Because
bladder and bowel tissue serve dif-
ferent metabolic purposes, the pro-
cedure results in complications.
Tengion’s ‘‘neobladder’’ is a three-
dimensional bioresorbable scaffold
layered with epithelial and smooth
muscle cells biopsied from the pa-
tient. In 6–8 weeks, the neobladder
grows enough to be implanted, after
which the body takes over the regen-
erative process and fills in the appro-
priate tissue layers and cell types.
Wrapping the organ in the omentum,
a sheath-like blood-vessel-rich tis-
sue in the abdomen, encourages
vascularization. Whether the appro-
priate neural connections can be
established is unclear, but the initial
patient population targeted has a
dysfunctional nervous system.
Tengion anticipates its first hu-
man trial of a bioengineered bladder
to take place at the end of 2006. ‘‘We
have had patients on wait lists for
years,’’ says Atala. ‘‘If we can guar-
antee them an organ in six months,
it is better than no organ at all.’’
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